Yamin Khan, CEO of Open Orphan PLC (AIM:ORPH, OTC:OPORF) talks to Proactive about a £14.7mln contract for an influenza characterization study to be followed by a challenge study.
It is Open Orphan’s first full-service, end-to-end award, its largest single contract to date and with a 'big pharma' repeat customer, he adds.
It follows just a few weeks after Open Orphan won its first contract as a clinical site.